Shuttle pharma announces proposed reverse stock split as part of strategic nasdaq compliance initiative

Gaithersburg, md., june 12, 2025 (globe newswire) -- shuttle pharmaceuticals holdings, inc. (nasdaq: shph) (“shuttle pharma” or the “company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (rt), announces that its board of directors have approved a proposed reverse stock split of its common stock at a ratio of 25-for-1. the proposed action remains subject to approval by nasdaq and, if approved, the company will issue a subsequent announcement disclosing the effective date.
NDAQ Ratings Summary
NDAQ Quant Ranking